As we enter year two of the pandemic, the way hospitals function now and in the future is forever changed. Photo via Getty Images

The COVID-19 pandemic has had a drastic effect on every industry throughout the world. Additionally, we have all experienced multiple changes to our daily routine such as schools implementing virtual and hybrid learning while reconfiguring classrooms to promote social distancing and fitness studios closing off every other cardio machine and bench.

But no industry has had to pivot and innovate more than health care, which has been ground zero for the pandemic.

The pace of innovation for hospitals has been at breakneck speed — from the evolution of new treatment protocols to the need to reconfigure physical spaces to support an influx of patients while also promoting a healing environment during this unprecedented time.

Hospitals look and feel a lot different today because of significant modifications that have been made to care for patients and limit exposure to the virus. While a number of these modifications occurred under temporary state waivers, some of these changes may be here to stay.

Adding windows and alternative communication options to every room

Hospitals found that every room is valuable during a pandemic. Identifying and converting any available space, including private rooms like offices, break rooms, and conference rooms, was essential to accommodate an influx of patients during a surge. And when dealing with a highly infectious area, it is imperative to maximize staff and physician efforts while also safely minimizing the amount of time that staff members enter and exit rooms.

One way to do this is by adding windows in doors to promote patient visibility. This increased visibility can improve patient safety while conserving critical personal protective equipment. However, a down side to limiting the amount of times staff members enter and exit rooms is reduced valuable communication opportunities, which is why alternative mechanisms to communicate with patients must be in place in addition to increased visibility.

Implementing additional negative pressure capabilities

Like adding windows to every patient door, negative pressure rooms exist to keep non-contaminated areas free of airborne pathogens. In a negative pressure room, the air in the room is pulled into a room instead of being pushed out of a room, which is very effective in preventing airborne contaminants from escaping the room and infecting other people. But hospitals are not traditionally built with significant numbers of negative pressure rooms as demand for these types of rooms has historically been low.

In addition, the traditional way to design a facility is to spread negative pressure rooms throughout the hospital instead of consolidating them onto specific units. Although not required for COVID-19 patients, negative pressure rooms are helpful in ensuring maximum capabilities within different zones. In instances where negative pressure rooms could not be created, HEPA filters can still be used to "scrub" the air.

Converting anesthesia machines to ventilators

Anesthesia machines are capable of providing life-sustaining mechanical ventilation to patients with respiratory failure from diseases like COVID-19. They are used for this purpose every day in the operating room. Although they are not recommended for long-term ventilator needs, anesthesia ventilators can be modified to provide ventilatory support and are an obvious first-line backup when there are not sufficient ICU ventilators to meet patient care needs.

Building barriers to increase the safety of care

Plexiglass barriers have become a common sight in daily life including the front desks at hospitals. However, hospitals have taken it a step further and have either built or sourced equipment such as intubation boxes, which can be used during the intubation process, which consists of placing a breathing tube into a patient's airway and then connecting it to a ventilator or anesthesia machine if the patient is having surgery. Intubations are often done by an anesthesiologist, intensive care or emergency room provider; however, traditionally we had not often dealt with highly-contagious patients, so providing a higher level of protection is an important step in the containment of this type of virus.

The way healthcare providers enter and exit a COVID patient's room is as important as the proper use of PPE. In a pre-pandemic world, hospitals didn't specifically create spaces or areas within patient floors for staff to remove and discard their PPE and there wasn't any visible signage warning them that they were about to enter or leave a high-risk area. Many hospitals across the country have implemented color-coded zones within their COVID floors to caution staff of the type of precautions they should be taking at any given time. The creation of zones helps to protect staff and reduce contamination opportunities within the unit itself. Red, yellow and green zones using visual markers can be created to help provide staff designated areas that certain processes must be followed such as where PPE must be worn, where it can be donned and doffed and where PPE should not be worn.

Managing complex logistical challenges

Hospitals have been challenged with having to continue to provide uninterrupted care for COVID and non-COVID patients during the pandemic, while also handling, storing and administering vaccines. Hospitals have been at the forefront of the vaccine distribution system, working closely with state and federal officials to distribute vaccines on a large scale and reach the underserved populations that were hit hardest by COVID-19. For example, Baylor St. Luke's chose Texas Southern University, located within the Third Ward of Houston, as a vaccine site to reach communities of color and leverage its accessible location and the school's pharmacy students and faculty. And more recently, the hospital worked with Rice University to administer vaccines at its football stadium, a large venue that can be accessed easily through public transportation. Having these offsite venues with ample space has helped alleviate the space burden on hospitals during the vaccination efforts. Non-traditional healthcare delivery locations like these allow health care providers to administer more doses, closer to targeted communities than would be possible at a single hospital.

As we enter year two of the pandemic, the way hospitals function now and in the future is forever changed. Hospitals continue to learn and adapt during the COVID-19 pandemic, and in case of another pandemic, hospitals are better equipped to quickly pivot to provide care for a surge of patients and to assist in the recovery efforts.

------

Liz Youngblood is president of Baylor St. Luke's Medical Center and senior vice president and COO of St. Luke's Health.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Play it back: Houston home tech startup begins 2025 with fresh funding

HOUSTON INNOVATORS PODCAST EPISODE 272

One of the dozen or so Houston startups kicking of the new year with fresh funding is SmartAC.com, a company that's designed a platform that enables contractors in the HVAC and plumbing industries to monitor, manage, and optimize their maintenance memberships through advanced sensors, AI-driven diagnostics, and proactive alerts.

Last month, the SmartAC.com raised a follow-on round with support from local investor Mercury to continue growth and expansion of the product, which has evolved on many ways since the company launched in 2020, emerging from stealth with $10 million raised in a series A. In a May 2023 interview for the Houston Innovators Podcast, Founder and CEO Josh Teekell explained how he embraced the power of a pivot.

The company's sensors can monitor all aspects of air conditioning units and report back any issues, meaning homeowners have quicker and less costly repairs. While SmartAC.com started with providing the service and tech to homeowners directly, Teekell says he's had a greater interest in working with plumbers and HVAC companies who then deploy the technology to their customers.

"It became quite evident that homeowners don't care about air conditioning really at all until their system breaks," Teekell says on the show. "The technology is really built around giving those contractors as another way to gain a customer relationship and keep it."

Revisit the podcast episode below where Teekell talks about SmartAC.com's last raise.

SmartAC.com's previous round in 2023 — a $22 million series B — was used grow its team that goes out to deploy the technology and train the contractors on the platform.

"We've been very fortunate to get some of the biggest names in Houston on our cap table," Teekell says in the May 2023 conversation. "Since we're raising a bunch of money locally, everyone understands what a pain air conditioning can be."

Houston biotech company tests hard-to-fight cancer therapeutics

fighting cancer

A Houston-based, female-founded biotech company has developed a treatment that could prove to be an effective therapy for a rare blood cancer.

Cellenkos Therapeutics has completed promising Phase 1b testing of its Treg cell therapy, CK0804, in the fight against myelofibrosis. According to a news release from the Cellenkos team, the use of its cord-blood-derived therapeutics could signal a paradigm shift for the treatment of this hard-to-fight cancer.

Cellenkos was founded by MD Anderson Cancer Center physician and professor Simrit Parmar. Her research at the hospital displayed the ability of a unique subset of T cells’ capability to home in on a patient’s bone marrow, restoring immune balance, and potentially halting disease progression.

Myelofibrosis has long been treated primarily with JAK (Janus Kinase) inhibitors, medications that help to block inflammatory enzymes. They work by suppressing the immune response to the blood cancer, but don’t slow the progression of the malady. And they’re not effective for every patient.

“There is a significant need for new therapeutic options for patients living with myelofibrosis who have suboptimal responses to approved JAK inhibitors,” Parmar says. “We are greatly encouraged by the safety profile and early signs of efficacy observed in this patient cohort and look forward to continuing our evaluation of the clinical potential of CK0804 in our planned expansion cohort.”

The expansion cohort is currently enrolling patients with myelofibrosis. What exactly are sufferers dealing with? Myelofibrosis is a chronic disease that causes bone marrow to form scar tissue. This makes it difficult for the body to produce normal blood cells, leaving patients with fatigue, spleen enlargement and night sweats.

Myelofibrosis is rare, with just 16,000 to 18,500 people affected in the United States. But for patients who don’t respond well to JAKs, the prognosis could mean a shorter span than the six-year median survival rate outlined for the disease by Cleveland Clinic.

Helping myelofibrosis patients to thrive isn’t the only goal for Cellenkos right now.

The company seeks to aid people with rare conditions, particularly inflammatory and autoimmune disorders, with the use of CK0804, but also other candidates including one known as CK0801. The latter drug has shown promising efficacy in aplastic anemia, including transfusion independence in treated patients.

The company closed its $15 million series A round led by BVCF Management, based in Shanghai, in 2021. Read more here.

Pioneering Houston biotech startup expands to Brazil for next phase

On the Move

Houston biotech company Cemvita has expanded into Brazil. The company officially established a new subsidiary in the country under the same name.

According to an announcement made earlier this month, the expansion aims to capitalize on Brazil’s progressive regulatory framework, including Brazil’s Fuel of the Future Law, which was enacted in 2024. The company said the expansion also aims to coincide with the 2025 COP30, the UN’s climate change conference, which will be hosted in Brazil in November.

Cemvita utilizes synthetic biology to transform carbon emissions into valuable bio-based chemicals.

“For decades Brazil has pioneered the bioeconomy, and now the time has come to create the future of the circular bioeconomy,” Moji Karimi, CEO of Cemvita, said in a news release. “Our vision is to combine the innovation Cemvita is known for with Brazil’s expertise and resources to create an ecosystem where waste becomes opportunity and sustainability drives growth. By joining forces with Brazilian partners, Cemvita aims to build on Brazil’s storied history in the bioeconomy while laying the groundwork for a circular and sustainable future.”

The Fuel of the Future Law mandates an increase in the biodiesel content of diesel fuel, starting from 15 percent in March and increasing to 20 percent by 2030. It also requires the adoption of Sustainable Aviation Fuel (SAF) and for domestic flights to reduce greenhouse gas emissions by 1 percent starting in 2027, growing to 10 percent reduction by 2037.

Cemvita agreed to a 20-year contract that specified it would supply up to 50 million gallons of SAF annually to United Airlines in 2023.

"This is all made possible by our innovative technology, which transforms carbon waste into value,” Marcio Da Silva, VP of Innovation, said in a news release. “Unlike traditional methods, it requires neither a large land footprint nor clean freshwater, ensuring minimal environmental impact. At the same time, it produces high-value green chemicals—such as sustainable oils and biofuels—without competing with the critical resources needed for food production."

In 2024, Cemvita became capable of generating 500 barrels per day of sustainable oil from carbon waste at its first commercial plant. As a result, Cemvita quadrupled output at its Houston plant. The company had originally planned to reach this milestone in 2029.

---

This story originally appeared on our sister site, EnergyCapitalHTX.